Mirtazapine

What are the side effects of Remeron – Mirtazapine?

• somnolence
• increased appetite
• weight gain
• dizziness.

• Strong CYP3A inducers: Dosage increase may be needed for REMERON/REMERONSolTab with concomitant use of strong CYP3A inducers.
• Strong CYP3A inhibitors: Dosage decrease may be needed when REMERON/REMERONSolTab is coadministered with strong CYP3A inhibitors.
• Cimetidine: Dosage decrease may be needed when REMERON/REMERONSolTab is coadministered with cimetidine.

• Agranulocytosis: If sore throat, fever, stomatitis or signs of infection occur, along with a low white blood cell count, treatment with REMERON/REMERONSolTab should be discontinued and the patient should be closely monitored.

• Serotonin Syndrome: Increased risk when co-administered with other serotonergic drugs (e.g., SSRI, SNRI, triptans), but also when taken alone. If it occurs, discontinue REMERON/REMERONSolTab and initiate supportive treatment.

• Angle-Closure Glaucoma: Angle closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants.

• QTc Prolongation: Use REMERON/REMERONSolTab with caution in patients with risk factors for QTc prolongation.

• Increased Appetite/Weight Gain: REMERON/REMERONSolTab has been associated with increased appetite and weight gain.

• Somnolence: May impair judgment, thinking and/or motor skills. Use with caution when engaging in activities requiring alertness, such as driving or operating machinery.

• Activation of Mania/Hypomania: Screen patients for bipolar disorder prior to initiating treatment.

• Seizures: Use with caution in patients with a seizure disorder.

• Elevated Cholesterol/Triglycerides: Has been reported with REMERON use.

• Hyponatremia: May occur as a result of treatment with serotonergic antidepressants, including REMERON/REMERONSolTab.

• Transaminase Elevations: Clinically significant elevations have occurred. Use with caution in patients with impaired hepatic function.